<DOC>
	<DOCNO>NCT02900157</DOCNO>
	<brief_summary>This open-label , study MEDI9090 evaluate safety , tolerability , PK , immunogenicity , antitumor activity MEDI9090 adult subject advance solid tumor .</brief_summary>
	<brief_title>Study Evaluate Safety Pharmacokinetics MEDI9090 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female subject 18 year old Must histologic documentation advance solid tumor Must receive progressed , refractory , intolerant standard therapy must curative therapy option Concurrent enrollment another clinical study Prior participation clinical study include durvalumab alone combination Concurrent chemotherapy , immunotherapy , biologic , hormonal therapy cancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>MEDI9090</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
</DOC>